Galera Therapeutics, Inc.
GRTX
$0.09
$0.00-4.61%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.46M | 5.69M | 5.92M | 8.06M | 9.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.73M | 6.04M | 6.16M | 8.47M | 11.54M |
| Operating Income | -5.73M | -6.04M | -6.16M | -8.47M | -11.54M |
| Income Before Tax | 149.04M | 149.05M | -8.99M | -13.38M | -16.37M |
| Income Tax Expenses | -- | -- | 0.00 | -203.00K | -203.00K |
| Earnings from Continuing Operations | 149.04 | 149.05 | -8.99 | -13.18 | -16.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 149.04M | 149.05M | -8.99M | -13.18M | -16.17M |
| EBIT | -5.73M | -6.04M | -6.16M | -8.47M | -11.54M |
| EBITDA | -4.06M | -6.02M | -6.14M | -8.45M | -11.52M |
| EPS Basic | 0.65 | 0.65 | -0.12 | -0.21 | -0.27 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.04 | -0.07 | -0.11 |
| EPS Diluted | 0.65 | 0.65 | -0.12 | -0.21 | -0.27 |
| Normalized Diluted EPS | -0.04 | -0.03 | -0.04 | -0.07 | -0.11 |
| Average Basic Shares Outstanding | 394.01M | 394.01M | 350.87M | 306.76M | 262.64M |
| Average Diluted Shares Outstanding | 394.01M | 394.01M | 350.87M | 306.76M | 262.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |